From: Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations
Author year | Country | Perspective | Time horizon | MHT duration base-case | MHT type | Discount Rate (%) | Year of costs | Cost per QALY | CE? | CIF? |
---|---|---|---|---|---|---|---|---|---|---|
Salpeter et al. 2009 [41] | USA | Societal | lifetime | 15 years | E + P&E (pooled data) | 3 | 2006 | Age 50: $2,438; | Yes | Yes |
Age 65: $27,953 | No | Yes | ||||||||
Lekander et al. 2009 [42] | UK | Health care | 50 years | 5 years | E + P(+U) E(-U) | 3 | 2006 | Age 50: |  | Yes |
£580(+U)a | Yes |  | ||||||||
£205(-U)a | Yes |  | ||||||||
Lekander et al. 2009 [43] | USA | Societal | 50 years | 5 years | E + P(+U) E(-U) | 3 | 2006 | Age 50: |  | Yes |
$2,803(+U) | Yes | Â | ||||||||
$295(- U) | Yes | Â | ||||||||
Ylikangas et al. 2007 [44] | Finland | Health care | 9 years | 9 years | E + P(+U) | 3 | 2003/2004 | Age 50–70: |  | Yes |
€2,996(+U) | Yes |  | ||||||||
(≤5 y MHT); |  |  | ||||||||
€4613(+U) | Yes |  | ||||||||
(≤9 y MHT); |  |  | ||||||||
Zethraeus et a.l 2005 [45] | Sweden | Societal | 50 years | 5 years | E + P(+) E(-U) | 3 | 2003 | Age 50: |  | Yes |
SEK 12,807Â (+U) | Yes | Â | ||||||||
SEK 8,266(- U); | Yes | Â | ||||||||
Age 55: | Â | Yes | ||||||||
SEK 10,844Â (+U) | Yes | Â | ||||||||
SEK 7,960(- U); | Yes | Â | ||||||||
Age 60: | Â | Yes | ||||||||
SEK 9,159(+U) | Yes | Â | ||||||||
SEK 11,043(-U); | Yes | Â |